Hims House

The hosts reflect on a transformative 2024, emphasizing the company's significant financial growth and brand evolution. They discuss new product launches, including weight loss treatments and erectile dysfunction solutions, while navigating market challenges and legal hurdles. Predictions for 2025 hint at exciting growth avenues and stock performance potential. With an eye on future innovations, they explore the impact of an AI-driven healthcare platform, and the implications of customer acquisition costs, keeping listeners engaged with the evolving market landscape.

In this episode of Hims House, Jonathan Stern, Louis Stevens, and Dr. H are joined by a special guest, Bayside, a professional lobbyist who works in Washington D.C. They discuss the recent FDA announcement about the tirzepatide shortage resolution and its implications on HIMS. Bayside shares insights from his 12-page research report, which accurately predicted this outcome, and provides a detailed analysis of FDA politics, the pharmaceutical industry, and future expectations for GLP-1 compounds like semaglutide. The episode also explores potential partnerships, legal challenges, and the role of personalized medicine in the context of compounding.00:00 Introduction00:31 FDA Announcement and Market Reaction00:53 Bayside's Research and Predictions04:27 Political and Legal Implications08:15 Semaglutide Shortage and Market Impact19:23 Court Filings and Hims Supply Tracker20:43 Reactions and Future Outlook21:22 FDA Regulations and Discretion22:35 Elon Musk's Influence and Motivations23:31 Compounding and Personalized Medicine26:01 Legal and Medical Perspectives on Dosage Variances31:01 Hims and the Pharmaceutical Industry36:25 Future of GLP-1 Drugs and Market Dynamics41:35 Speculations and Future Partnerships Get full access to Hims House at himshouse.substack.com/subscribe

Dive into the effects of Meta's data restrictions on healthcare marketing strategies. Discover how Hims navigates these changes, drawing parallels with past privacy challenges. The podcast also highlights a pivotal partnership between Ro and Lilly, reshaping telehealth's landscape. Key concerns about compounded GLP-1 medications from the American Diabetes Association raise alarms over safety and efficacy. These discussions emphasize the importance of informed patient care and navigating the complexities of modern medicine.

Subscribe to Hims House!Website: himshouse.substack.comTwitter/X: x.com/himshouseDiscord: discord.gg/tJqGgVhkEtFollow us on Twitter/X:Jonathan Stern - x.com/jonathanrsternLouis Stevens - x.com/LA_stevens_Dr. H - x.com/stayathomedocIn Episode 14 of Hims House, host Jonathan Stern is joined by Louis Stevens and Dr. H to discuss the FDA's delayed decision on terzepatide shortages, its implications for Hims, and how it may reflect on semaglutide. They dive into the importance of anchoring to the long-term vision of Hims amid market volatility and debate the FDA’s growing acknowledgment of the medication shortage. The team also explores the newly launched meal replacement bars and shakes by Hims and their potential impact on the business. They further discuss the market reactions, the diverse weight loss product range, and the integral understanding needed for sustainable growth in the telehealth and wellness space.00:00 Introduction and Episode Overview00:30 FDA Decision on Terzapatide Shortage01:04 Impact on Hims and Market Reactions01:35 Review of FDA's Actions and Industry Reactions05:31 Discussion on Compounded Medications11:34 Remembering the Long-Term Thesis for Hims28:58 New Product Launch: Meal Replacement Bars and Shakes Get full access to Hims House at himshouse.substack.com/subscribe

In Episode 13 of Hims House, Jonathan Stern, Louis Stevens, and Dr. H discuss the implications of Amazon's telemedicine announcements on Hims & Hers. They examine Amazon's pricing, offerings, and potential market overlap with Hims, while exploring whether this presents a serious threat or is overhyped by speculative narratives on platforms like Twitter. The conversation transitions to Hims’s strategic positioning, emphasizing customization, trust, and long-term customer relationships as competitive advantages. The team also delves into the regulatory uncertainty surrounding GLP-1 medications and how Hims is positioning itself with alternative treatments to address future challenges.00:00 Welcome and Introduction00:14 Amazon's New Pricing Announcement01:31 Impact on Hims and Market Reactions03:41 Patient Preferences and Pricing06:50 Bear Arguments in Response To the News12:09 Amazon Not Doing Weight Loss13:33 Historical Context of Market Competition23:56 Customer Base Overlap Between Amazon Prime and Hims35:57 GLP-1 Supply Tracker and Regulatory Challenges46:21 ConclusionWebsite: https://himshouse.substack.comTwitter/X: @himshouseDiscord: https://discord.gg/tJqGgVhkEtJonathan Stern - @jonathanrsternLouis Stevens - @LA_stevens_Dr. H - @stayathomedoc Get full access to Hims House at himshouse.substack.com/subscribe

Delve into the exciting financial landscape of Hims & Hers Health as they celebrate surpassing 2 million subscribers. The discussion spotlights the booming interest in personalized solutions and the anticipated launch of liraglutide for weight management. Key financial metrics reveal impressive growth, raising eyebrows amidst market skepticism. Explore the evolving role of multi-product strategies and the potential for meal replacements, all while navigating the intricate trends of personalized medicine and consumer engagement.

In this episode of Hims House, Jonathan Stern, Louis Stevens, and Dr. H provide a comprehensive preview of Hims' upcoming Q3 2024 earnings report. They discuss past earnings performance, market reactions, volatility, and expectations for future earnings. Key points include Hims' historical revenue growth, the impact of GLP-1 medications, vertical integrations, and forward-looking projections for the company. The discussion highlights the importance of customer acquisition costs, the value of the new 503B pharmacy, and the anticipation of new product launches. Additionally, the team provides insights into investor sentiment and potential stock price movements post-earnings report.00:00 Introduction and Overview00:18 Setting the Stage for Q3 Earnings00:27 Historical Performance and Market Reactions03:26 Q2 2024 Recap and Expectations05:17 Insights from Dr. H on Telehealth and GLP-106:44 Hims' Revenue Guidance and Projections10:47 Discussion on Business Growth and Sustainability13:37 Product Announcements and Future Roadmap25:08 503B Pharmacy Acquisition and Vertical Integration30:13 Earnings Predictions and Stock Price Projections Get full access to Hims House at himshouse.substack.com/subscribe

In episode 10 of Hims House, Jonathan Stern, Louis Stevens, and Dr. H interview Sekander Amini, a UK-based pharmacist and long-time Hims investor. Sekander shares insights about how his pharmacy mirrors Hims' model by offering premium services like mental health and weight loss medications. He highlights Hims' advantages in compounding medications, simplifying treatment adherence, and leveraging technology for better patient care. The group discusses the healthcare landscape in the UK, touching on public versus private care and the potential growth opportunity for Hims. They also explore Hims' focus on premium experiences, the role of AI in healthcare, and what investors should watch for in the upcoming earnings call.00:00 Introduction and Sekander Amino Welcome00:52 Day-to-Day at the Private Pharmacy03:24 Initial Investment in Hims03:51 Hims' Price Transparency and Accessibility05:46 Compounded Medications and Personalized Care07:07 Premium Experience and Product Evolution15:59 Comparing UK and US Healthcare Systems20:53 Opportunities in the UK Market23:09 Hims' Generic Offerings23:30 UK Healthcare System Overview24:19 Hims' Market Potential in the UK24:48 Compounding Pharmacies in the UK25:40 Challenges in International Expansion27:10 Hims' Strategic Focus34:18 MedMatch and Mental Health40:14 International Expansion Concerns44:09 Q3 Earnings Expectations45:54 Closing Remarks and Farewell Get full access to Hims House at himshouse.substack.com/subscribe

In Episode 9 of Hims House, Jonathan Stern, Louis Stevens, and Dr. H discuss potential product expansions for Hims & Hers, focusing on menopause, testosterone, fertility, and diabetes. They highlight menopause as a low-hanging opportunity due to minimal medical oversight requirements, while testosterone presents logistical challenges with necessary blood testing and monitoring. The conversation delves into Hims' methodical product rollout strategy, suggesting that they time launches carefully to ensure consistent growth. The episode also explores Hims' use of vertical integration with its 503B compounding facility and the potential implications of their recent inclusion in the S&P Small Cap 600 index.(00:00) - Introduction(00:42) - Menopause as an opportunity(03:33) - Testosterone overview(06:10) - Diabetes Management and Livongo Comparison(10:45) - Logistical Challenges with Testosterone Treatment(24:03) - 503B Compounding Facility Now Hiring(29:24) - Hims Moneyball Comparison(34:52) - Weight Watchers GLP-1 Offering and Impact on Hims(38:55) - Inclusion in S&P Small Cap 600Website: https://himshouse.comTwitter/X: @himshouseDiscord: https://discord.gg/WPzMX448V8Jonathan Stern - @jonathanrsternLouis Stevens - @LA_stevens_Dr. H - @stayathomedoc Get full access to Hims House at himshouse.substack.com/subscribe

A deep dive into the financial health of a leading telehealth company reveals impressive subscriber growth, reaching nearly 2 million. Personalized medications are driving retention and shaping a sustainable business model. The discussion emphasizes the balance between customer acquisition costs and cash flow, highlighting significant metrics such as gross profit and average revenue per user. Despite concerns about marketing spend, the company emerges as a strong long-term investment, outperforming expectations in a competitive market.